Sacubitril/valsartan cut AFib recurrence after ablation in older hypertensive adults
A blood pressure regimen built around sacubitril/valsartan was associated with fewer recurrent atrial arrhythmias after catheter ablation than valsartan alone in a randomized trial of older adults with hypertension and atrial fibrillation. At 12 months, documented recurrence of atrial tachyarrhythmias occurred in 18% of patients assigned to the combination drug and 28.3% of those assigned to valsartan alone.
The signal is striking because blood pressure fell by about the same amount in both groups. In other words, the benefit did not appear to come from simply lowering systolic pressure a little more aggressively.
The study was presented as a late-breaking science abstract at the American Heart Association’s Scientific Sessions 2026, so the findings remain preliminary until full peer-reviewed publication. Still, the data point to a clinically important question in post-ablation care: whether the choice of antihypertensive agent can influence the heart’s rhythm stability after the catheter has already done its electrical work.
Why the rhythm outcome may extend beyond blood pressure numbers
Ablation targets the abnormal electrical activity driving atrial fibrillation, but it does not erase the atrial remodeling that often accompanies long-standing hypertension. Elevated pressure can enlarge the heart, raise filling pressures and promote scarring within atrial tissue. Those structural changes create an environment in which arrhythmia can return even after an initially successful procedure.
Sacubitril/valsartan adds a second biologic pathway beyond angiotensin receptor blockade. Valsartan blocks the angiotensin II type 1 receptor, while sacubitril inhibits neprilysin after conversion to an active metabolite, preserving natriuretic peptides. That combination may influence myocardial stretch, neurohormonal activation and tissue remodeling in ways that go beyond office blood pressure readings. The trial cannot prove mechanism, but the pattern is consistent with a drug effect on atrial substrate rather than a simple hemodynamic effect.
AFib recurrence after ablation can mean return of symptoms, repeat monitoring, additional antiarrhythmic treatment and, for some patients, another ablation procedure.
Trial design and patient profile
The randomized, controlled trial enrolled 320 patients with both atrial fibrillation and hypertension, defined as clinic blood pressure above 130/80 mm Hg, who underwent catheter ablation at three hospitals in China between February 2023 and January 2025. The average age was 68 years, 41.2% were women and 66.6% had paroxysmal AFib, meaning the arrhythmia came and went in episodes rather than persisting continuously.
After ablation, 161 patients were assigned to sacubitril/valsartan at 100 mg once daily and 159 were assigned to valsartan at 80 mg once daily. Because all participants required treatment for hypertension, valsartan served as an active comparator rather than placebo. That choice matters clinically: it isolates the question of whether a specific blood pressure strategy changes rhythm recurrence, not whether treating hypertension at all is useful. Treating hypertension remains essential in both groups.
Follow-up lasted 12 months, with visits scheduled at 1, 3, 6 and 12 months. Rhythm surveillance included handheld single-lead ECG devices for home monitoring, standard 12-lead ECGs and 24-hour Holter monitoring at visits. Documented recurrence was centrally adjudicated by an independent team blinded to treatment assignment, even though the trial itself was open-label.
What changed, and what did not
The recurrence curves separated despite similar blood pressure control. Systolic blood pressure fell by about 10 mm Hg in both groups, and there was no significant difference in the reduction in 24-hour ambulatory blood pressure between the treatment arms.
The absence of a blood pressure gap is the most clinically interesting part of the trial.
If rhythm benefit had tracked neatly with greater pressure lowering, the finding would have been easy to explain. Instead, the data suggest that atrial protection may come from the pharmacology of sacubitril/valsartan itself, or from a downstream effect on atrial remodeling that is not captured by routine blood pressure measurement. For clinicians, that raises a practical issue after ablation: hypertension management may not be interchangeable if the goal is not only vascular protection but also suppression of recurrent atrial arrhythmias.
Wei Zhang, M.D., Ph.D., the study’s lead author, said the findings reinforce that AFib treatment does not end with the ablation procedure and that hypertension remains a key part of comprehensive care. He also emphasized that the results should not be read as proof that ablation alone or medication alone is sufficient to prevent recurrence. Long-term rhythm control still depends on both procedural success and aggressive management of underlying cardiovascular risk.
Limits that keep the result from overreaching
Several features narrow the interpretation. The trial was open-label, so patients and treating physicians knew the assigned medication. Heart rhythm monitoring was intermittent rather than continuous, so brief or symptom-free episodes may have been missed. The study also focused on older adults with hypertension undergoing AFib ablation in China, which limits direct generalization to younger patients, people without hypertension and those treated in other settings.
Even with those constraints, the result is not trivial. Recurrence after ablation remains a common and frustrating problem, particularly in patients whose atria have already been altered by years of pressure load. A therapy that reduces recurrence without lowering blood pressure more than standard therapy suggests that atrial biology itself is being influenced.
The study was supported by grants from Chinese national and Shanghai research programs, as well as the Clinical Research Program of Ruijin Hospital. Funders had no role in study design, data handling, manuscript preparation or the decision to submit the results.
For now, the trial does not settle whether sacubitril/valsartan should become standard after ablation. It does show that the choice of antihypertensive agent may matter in a population where rhythm stability depends on more than pressure control alone.